You are here

Article Text

Article menu
Download PDFPDF
EBM opinion and debate
General medicine
Is clinical effectiveness in the eye of the beholder during the COVID-19 pandemic?

https://doi.org/10.1136/bmjebm-2020-111423

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Twitter @JLSandoval, @dralexgva, @alfdoc2

    • Contributors All authors have contributed to drafting the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests AA has received compensation from Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Takeda, Pfizer, Roche and Boehringer Ingelheim for participating on advisory boards. AF has received compensation from Roche, Pfizer, Astellas and Bristol-Myers Squibb for service as a consultant.

    • Provenance and peer review Not commissioned; externally peer reviewed.